Intensity Therapeutics, Inc. announced on November 8, 2024, that its Phase 3 INVINCIBLE-3 trial has been selected for an oral podium presentation at the 2024 Connective Tissue Oncology Society (CTOS) meeting. The presentation is scheduled for November 16, 2024. Dr. Christian F. Meyer will highlight completed Phase 2 results and the design of the INVINCIBLE-3 randomized soft tissue sarcoma trial.
The CTOS conference, an international gathering of physicians and scientists focused on connective tissue tumors, will take place from November 13 to 16, 2024. This selection provides a platform for Intensity Therapeutics to disseminate important information about its lead drug candidate, INT230-6. The presentation will cover the study criteria for the INVINCIBLE-3 trial.
The INVINCIBLE-3 study is a global randomized Phase 3 trial designed to evaluate INT230-6 as a monotherapy compared to standard of care in soft tissue sarcoma. This presentation at a prominent oncology society meeting underscores the scientific interest in Intensity's novel intratumoral cancer therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.